Oxaliplatin Accord

Oxaliplatin, the active ingredient in Oxaliplatin Accord, is a platinum‑based chemotherapy presented as a 100 mg/5 ml solution for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin Accord is a platinum‑based agent used in the treatment of cancers that involve the colorectal pathway and related solid tumours.

- Colorectal cancer: improves progression‑free survival when combined with fluorouracil‑based regimens. - Gastric cancer: used in combination protocols for advanced disease. - Pancreatic cancer: contributes to tumour response as part of multi‑drug regimens. - Ovarian cancer: employed in certain platinum‑sensitive relapse settings. - Esophageal cancer: added to standard chemotherapy for metastatic cases. - Small‑cell lung cancer: used off‑label in some combination therapies.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during treatment.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: watery stools that may require supportive care. - Fatigue: generalized tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count, increasing bleed risk. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical intervention. - Acute hemolytic anemia: rapid destruction of red blood cells. - Severe neutropenia: markedly low neutrophil count, raising infection risk. - Cardiotoxicity: rare heart rhythm disturbances. - Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnoea. - Renal impairment: acute kidney injury in susceptible patients.

Before initiating Oxaliplatin Accord, clinicians should assess patient suitability and monitor key parameters throughout therapy.

- Renal function: evaluate creatinine clearance before each cycle. - Hepatic function: check liver enzymes and bilirubin levels regularly. - Neuropathy risk: assess baseline peripheral nerve status and adjust dose if symptoms worsen. - Hematologic monitoring: perform complete blood counts to detect cytopenias. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Storage: Store below 25°C: keep in the original container, protect from light and moisture.

Oxaliplatin can interact with several drug classes, influencing efficacy or toxicity. Careful review of concomitant medications is essential.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use may exacerbate renal injury. - Myelosuppressive chemotherapy: combined effect can cause severe cytopenias. - High‑dose vitamin C: may reduce platinum‑drug activity.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk due to thrombocytopenia. - Antihypertensives: potential for altered blood pressure control. - Proton‑pump inhibitors: may affect gastrointestinal tolerance. - Anticonvulsants: possible additive neurotoxicity. - Herbal supplements: unpredictable effects on drug metabolism.